Findings from the current study support reduced function of OATP1B1, OATP1B3, and MRP2 in MASH, highlighting the potential for altered disposition of drugs transported by these pathways in MASH patients. The gene discussed is SLCO1B1; the disease is metabolic dysfunction-associated steatohepatitis.